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Abstract
Background: Surgeons agree on the benefits of operative treatment of tibial fractures – the most
common of long bone fractures – with an intramedullary rod or nail. Rates of re-operation remain high –
between 23% and 60% in prior trials – and the two alternative nailing approaches, reamed or non-reamed,
each have a compelling biological rationale and strong proponents, resulting in ongoing controversy
regarding which is better.
Methods/Design: The objective of this trial was to assess the impact of reamed versus non-reamed
intramedullary nailing on rates of re-operation in patients with open and closed fractures of the tibial shaft.
The study to prospectively evaluate reamed intramedullary nails in tibial fractures (S.P.R.I.N.T) was a multi-
center, randomized trial including 29 clinical sites in Canada, the United States and the Netherlands which
enrolled 1200 skeletally mature patients with open (Gustilo Types I-IIIB) or closed (Tscherne Types 0–3)
fractures of the tibial shaft amenable to surgical treatment with an intramedullary nail. Patients received a
statically locked intramedullary nail with either reamed or non-reamed insertion. The first strategy
involved fixation of the fracture with an intramedullary nail following reaming to enlarge the intramedullary
canal (Reamed Group). The second treatment strategy involved fixation of the fracture with an
intramedullary nail without prior reaming of the intramedullary canal (Non-Reamed Group). Patients,
outcome assessors, and data analysts were blinded to treatment allocation. Peri-operative care was
standardized, and re-operations before 6 months were proscribed. Patients were followed at discharge, 2
weeks post-discharge, and at 6 weeks, 3, 6, 9, and 12 months post surgery. A committee, blinded to
allocation, adjudicated all outcomes.
Discussion: The primary outcome was re-operation to promote healing, treat infection, or preserve the
limb (fasciotomy for compartment syndrome after nailing). The primary outcome was a composite
comprising the following re-operations: bone grafts, implant exchanges, and dynamizations, in patients with
fracture gaps less than 1 cm post intramedullary nail insertion. Infections and fasciotomies were considered
events irrespective of the fracture gap. We planned a priori to conduct a subgroup analysis of outcomes in
patients with open and closed fractures. S.P.R.I.N.T is the largest collaborative trial evaluating alternative
orthopaedic surgical interventions in patients with tibial shaft fractures. The methodological rigor will set
new benchmarks for future trials in the field and its results will have important impact on patient care. The
S.P.R.I.N.T trial was registered [ID NCT00038129] and received research ethics approval (REB#99-077).
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Background
The S.P.R.I.N.T trial protocol was developed as a multi-
center, blinded randomized controlled trial (RCT) to
compare alternative intramedullary techniques in 900
patients with closed and open tibial shaft fractures. The
trial received joint funding from the Canadian Institutes
of Health Research and the National Institutes of Health.
This article provides the rationale and design of the origi-
nal S.P.R.I.N.T protocol. We also provide a detailed report
of the major protocol changes made during the study exe-
cution. Specifically, we present changes made in response
to the first interim analysis including a revision of our
sample size estimates and a refinement of the primary
composite outcome.
Magnitude of the problem
Fractures of long bones constitute the majority of emer-
gency operating room procedures in most trauma centres.
Of these long bone injuries, tibial fractures are the most
common. The National Center for Health Statistics
reports an annual incidence of 492,000 fractures of the
tibia and fibula per year in the United States [1]. Patients
with tibial fractures remain in hospital for a total of
569,000 hospital days and incur 825,000 physician visits
per year in the United States [1].
Tibial fractures are prone to complications [2-5]. The lack
of a circumferential soft tissue envelope around the bone
makes the bone ends more likely to fail to unite (nonun-
ion). Approximately 50,000 North Americans suffer each
year from these nonunion complications [6]. Nonunions
may require secondary operations to promote fracture
healing. In addition to the risk of general anesthesia and
early post-operative venous thromboembolism complica-
tions [7-9], patients who require re-operation face addi-
tional rehabilitation and time off work. Furthermore, re-
operations result in substantial resource consumption
and indirect costs due to decreased productivity. Manage-
ment strategies to best minimize these frequent complica-
tions and resulting re-operations have proved
controversial.
Historical management of tibial fractures
Over the last 20 years, surgeons have used four manage-
ment approaches for tibial fractures: intramedullary nail
fixation [10-12], plate fixation [13], external fixation [14]
and casting or functional bracing [15-17]. While it may be
preferable to cast a closed tibial shaft fracture, most sur-
geons agree that in certain unstable fracture patterns, casts
will not maintain adequate fracture alignment [18]. In
recent years, surgeons have moved away from plates and
external fixators in favour of intramedullary nails in the
operative treatment of both closed and open tibial frac-
tures [19]. To clarify this issue, we conducted a meta-anal-
ysis examining evidence regarding the treatment of open
tibial fractures. We identified randomized trials (RCTs)
comparing plates with external fixators [20] and
intramedullary nails with external fixators [21-25]. The
pooled estimate from 5 studies (n = 396 patients) that
compared external fixators to non-reamed intramedullary
nails showed a large reduction in the risk of re-operation
with non-reamed nails, and an associated narrow confi-
dence interval (relative risk 0.51, 95% CI 0.37–0.69) [21-
25]; therefore, we can be confident that intramedullary
nailing will reduce the rate of re-operation by over one
third. Although most surgeons agree that intramedullary
nails are the preferred treatment, the choice of reamed ver-
sus non-reamed nail insertion remains controversial.
Rationale for the two dominant approaches
Surgeons currently favor the use of interlocking intramed-
ullary nails to reduce both nonunion and infection rates;
however, they do not agree on the optimal approach to
nailing. Reaming of the medullary canal, with placement
of a large nail to ensure optimal biomechanical stability
while promoting healing, and the use of a non-reamed
nail, to maintain blood flow to the cortical bone to pro-
mote healing, both have strong rationale and ardent advo-
cates.
Reamed Intramedullary Nails
Research supporting the use of reamed intramedullary
nails has focused on the increased blood flow to soft tis-
sues and the superior biomechanical stability of reamed
nails. For example, Schemitsch et al have shown in a
sheep tibial fracture model that reaming prior to nail
insertion significantly increases muscle and surrounding
soft tissue blood flow in comparison to unreamed nails.
This increase persists for up to 6 weeks [26]. Utvag et al
confirmed these findings in a rat femoral fracture model
[27]. Increased blood flow to soft tissue may also improve
cortical blood flow: Grundnes and colleagues have dem-
onstrated 5-fold increases in cortical blood flow following
reamed nailing of rat femurs when compared to the con-
trol [28]. In addition to possible advantages from
increased blood flow, investigators have documented the
biomechanical superiority of large diameter nails versus
smaller diameter nails [29,30].
Non-Reamed Intramedullary Nails
Massive destruction of the endosteal blood supply (up to
70%) following intramedullary reaming has been inde-
pendently reported by Rhinelander and Olerud [31-33].
In a canine tibial fracture model, Klein et al. have shown
that non-reamed nailing also disturbs cortical circulation
[34]. Using a similar model, Hupel et al. have demon-
strated that a non-reamed intramedullary nail allows
superior cortical revascularization at 11 weeks when com-
pared to a tight-fitting nail [35]. Schemitsch has shownBMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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that significant increases in cortical bone porosity are
associated with reamed intramedullary nails [36].
In summary, experimental data suggest that reamed nails
offer greater biomechanical stability and increased soft tis-
sue blood flow, while non-reamed nails preserve blood
flow to the bone. While both arguments are persuasive,
evidence of the impacts of these biologic alterations on
outcomes that are important to patients would be more
compelling data in guiding clinical practice.
Reamed and non-reamed nails: effect on important 
outcomes
Both nonunion of the bone [37-40] and infection at the
implant-bone interface [41,42] may necessitate a second
operation to promote fracture healing. Because of the risks
and costs to the patient, and the costs to the health care
system, reoperation represents an important outcome
from both individual and societal points of view. Our
meta-analysis of RCTs [43] suggested that reamed
intramedullary nailing of lower extremity femoral and tib-
ial bone fractures results in significantly fewer nonunions
than non-reamed nailing [44-52] (pooled relative risk
0.33, 95% CI 0.16 to 0.68). Evaluation of fracture sub-
groups further suggested a large treatment effect favoring
reamed nails in femoral fractures (relative risk: 0.24, 95%
CI, 0.07–0.82), but a less persuasive effect in tibial frac-
tures (relative risk 0.44, 95%CI 0.21–0.93) [43].
Because the biology of open tibial fractures is different
from that of closed fractures, the relative impact of reamed
and non-reamed nailing may differ in these sub-popula-
tions. The significant soft tissue damage and stripping of
the periosteum from the cortical bone, which is common
in open fractures, has the potential to compromise blood
supply to that region [53]; therefore, the preservation of
endosteal, or intramedullary, blood supply may be more
important. Opponents of reamed nails believe that the
disruption of endosteal blood supply, as a result of
intramedullary reaming, increases the risk of nonunion
for the fracture.
To clarify this issue, we conducted a second meta-analysis
examining evidence regarding the treatment of open tibial
fractures [54]. We identified two small RCTs that com-
pared reamed and non-reamed intramedullary nails. The
small sample sizes (total n = 132) in the two studies that
have compared reamed nails [44,50] is reflected in the
wide confidence intervals around the trend in favor of
reamed nails in the risk of re-operation (0.75, 95% CI,
0.43–1.32) in comparison to non-reamed nails. The
trends in favor of reamed nails in open tibial fractures are
consistent with findings of our prior meta-analysis.
Is the answer in for tibial fractures?
Despite the results of these two meta-analyses, uncertainty
about the optimal treatment for tibial fractures remains.
Reasons for this uncertainty ensue:
1. The tibia differs biologically from the femur because it
does not have a circumferential soft tissue envelope that
partly provides the blood supply to the bone. While the
intact soft tissue envelope around the femur is adequate to
maintain blood supply to the bone and promote fracture
healing following intramedullary reaming, this may not
be the case for tibial shaft fractures. Thus, the biological
case for reaming is weaker in tibial fractures.
2. While the evidence from our first meta-analysis strongly
favours the use of reamed intramedullary nails in the
treatment of femoral fractures (relative risk: 0.24, 95% CI,
0.07–0.82), the effects of reamed nails in tibial fractures
are not as persuasive (relative risk 0.44, 95%CI
0.21–0.93) [43].
3. Current opinions in the treatment of tibial shaft frac-
tures among orthopaedic traumatologists remain diver-
gent. We previously surveyed a 20% random sample of
members of the Canadian Orthopaedic Association. Of
the 60 respondents who treat tibial fractures, 35 (58%)
indicated that they thought reamed nails were superior
and 25 indicated (42%) that they thought non-reamed
nails were the same or better than reamed nails. For open
tibial fractures: 31 (52%) believed non-reamed nails were
superior whereas 29 (48%) believed reamed nails were
the same or better. The results demonstrate a lack of pre-
dominant nail preference for both open and closed frac-
tures. Our findings were supported in a large international
survey of surgeons (Table 1).
Only a large RCT would resolve the remaining, legitimate,
scientific uncertainty, and the continuing controversy in
the clinical community.
Methods/Design
The primary objective was to assess the impact of reamed
and non-reamed intramedullary nailing on rates of re-
operation (including nail exchange, bone grafts, dynami-
zation, and fasciotomy) in patients with post-operative
fracture gaps less than 1 cm following intramedullary nail-
ing and re-operation for deep infection irrespective of the
post-operative fracture gap.
The secondary objective was to assess the impact of
reamed and nonreamed intramedullary nailing on func-
tional status (Short Form-36 (SF-36), Short Musculoskel-
etal Functional Assessment (SMFA), Health Utilities Index
(HUI), Tibia Knee Pain Questionnaire) and return to nor-
mal activities.BMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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Trial design
We initially proposed to enroll 900 patients in a prospec-
tive, RCT in which surgeons managed individuals who
sustained a fracture of the tibia by one of two strategies.
The first strategy involved fixation of the fracture with an
intramedullary nail following reaming of the intramedul-
lary canal (Reamed Group). The second treatment strategy
involved fixation of the fracture with a smaller intramed-
ullary nail without prior reaming of the intramedullary
canal (Non-Reamed Group). Patients enrolled in the trial
received post-operative care according to the same stand-
ards and protocols. We monitored critical aspects of pre-
operative and post-operative care and provided immedi-
ate feedback to the participating surgeons when any
important deviation from protocol occurred. Patients,
outcome assessors, and data analysts were blinded to
treatment allocation. We monitored re-operation rates at,
discharge, 2 weeks post discharge, 6 weeks, 3, 6, 9, and 12
months. In patients with prolonged hospital stays, post-
operative follow up forms were completed at their sched-
uled times and the 2 week post discharge form was com-
pleted as originally described (two weeks after the
discharge date regardless of hospital stay). We received
research ethics approval (REB#99-077) for this study.
Trial interventions
Reamed nail insertion
Reaming was conducted over the guide wire with cannu-
lated power reamers. The operating surgeon chose the
reamer. To avoid inconsistencies in the degree of reaming,
surgeons adhered to the following protocol: 1) Surgeons
reamed the intramedullary canal until the first detection
of "cortical chatter" (i.e. the reamer just begins to contact
the cortical bone of the tibia). 2) The size of the nail
(diameter) corresponded to the point of "cortical chatter"
(if chatter occurred with a 11 mm reamer, then the nail
size is 11 mm. 3) Following the appearance of "cortical
chatter", surgeons reamed 1–1.5 mm larger than the cho-
sen nail's diameter to facilitate its insertion. The chosen
nail, which was as long as possible without distracting the
fracture by impinging on dense distal metaphyseal bone
or protruding above the cortex at the insertion site, was
inserted with the appropriate instruments. Distraction of
a tibial shaft fracture interferes with healing, so surgeons
employed all strategies for achieving cortical contact (up
to 10 mm shortening acceptable to achieve contact of frac-
ture ends). The choice of intramedullary nail (i.e. com-
pany) and material (titanium or stainless steel) was at the
discretion of the operating surgeon.
Non-reamed nail insertion
Surgeons inserted non-reamed nails across the fracture
site with great attention to the prevention of over-distrac-
tion. The goal was to achieve cortical contact of the frac-
ture ends. An upper diameter limit of 10 mm was
employed for non-reamed nails. Surgeons were instructed
that in principle, the nail should be at least 2 mm less than
the diameter at the isthmus of the tibia on anteroposterior
and lateral radiographs.
Interlocking screws
All fractures were interlocked, both proximally and dis-
tally. Surgeons used at least one proximal locking screw
and one distal locking screw. The number of screws, one,
two, or three was left to the discretion of the surgeon.
Peri-operative treatment common to both groups
To ensure similar peri-operative regimens, participating
centres standardized key aspects of pre- and post-opera-
tive care.
Table 1: Implant preference among surgeons (N = 444)
Type of Fracture Type of Implant (%)
External Fixator Plate IM Nail (Reamed) IM Nail (Non-Reamed)
CLOSED FRACTURES
Closed Fractures (Low Energy) * 0.5 3.2 76.0 20.3
Closed Fractures (High Energy) 1.8+ 2.1 60.4+ 35.6+
Closed Fractures with Compartment Syndrome 12.2+ 7.4+ 34.9+ 45.5+
OPEN FRACTURES
Grade I Open Fractures 3.4 1.1 54.5 41.0
Grade II Open Fractures 11.1# 0.8 46.3# 41.8
Grade IIIa Open Fractures 30.6# 1.1 28.8# 39.6
Grade IIIb Open Fractures 50.5# 1.1 13.6# 34.8
* 0.8% respondents treated all injuries by non-operative methods. IM = intramedullary
+ significant difference when compared to responses for closed fractures (low energy)
# significant difference when compared to responses for Grade I open fractures (p < 0.01)
From: Bhandari M, Guyatt GH, Swiontkowski MF, Tornetta P 3rd, Hanson B, Weaver B, Sprague S, Schemitsch EH. Surgeons' preferences for the 
operative treatment of fractures of the tibial shaft. An international survey. J Bone Joint Surg Am. 2001;83-A:1746-52BMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
Page 5 of 15
(page number not for citation purposes)
In Closed Fractures: 1) Pre-operative antibiotic adminis-
tration was continued for 24 hours post-operatively (spe-
cific antibiotic regimens at the discretion of the operating
surgeon: gram positive coverage). 2) Cortical contact of
the fracture ends guided weight bearing. If cortical contact
was achieved, patients were allowed to weight bear as tol-
erated. However, when cortical contact was not achieved,
patients are allowed to partially weight bear on the
affected limb until a definitive procedure to achieve con-
tact was performed. 3) Dynamization, a technique in
which the interlocking screws are removed distally to
allow compression at the fracture site, was allowed prior
to 6 months only if the fracture is distracted following nail
insertion. 4) Participating surgeons did not offer stimula-
tion modalities to promote bone growth including ultra-
sound and electrical stimulation during the one-year of
follow-up.
In Open Fractures: 1) Pre-operative intravenous antibiotic
administration included a cephalosporin and an
aminoglycoside which were continued for 72 hours post-
operatively (specific antibiotics used at the discretion of
the attending surgeon. The recommended guidelines
included: cephalosporin (ancef) I.V. for Grade I-II inju-
ries, ancef I.V. and aminoglycoside (gentamycin) I.V. for
Grade III injuries, and ancef I.V., gentamycin I.V. and pen-
icillin for gross contaminated injuries). 2) Copious irriga-
tion and debridement of soft tissues and contaminated
bone was repeated as necessary, 3) Delayed wound clo-
sure, split thickness skin grafting, or muscle flaps (for
grade IIIB only) occurred by 7 days following the initial
surgery. 4) Weight bearing, dynamization, and the use of
stimulation modalities as per closed fractures.
Randomization
We stratified patients by centre and according to whether
they had sustained a closed or open fracture of the tibia.
We randomized in blocks; clinical centres were unaware
of the block size. We defined the patient as the unit of ran-
domization. Therefore, single patients with bilateral tibial
shaft fractures were randomized to one treatment alterna-
tive only. Both fractures were treated with either reamed
or non-reamed nailing. We anticipated that randomiza-
tion would lead to approximately the same number of
such patients in the two groups. We considered single or
bilateral fractures as an additional stratification variable,
but decided that the risk of empty cells was too great.
The research coordinator or resident/fellow ensured that
the patient met all eligibility and, as close to surgery as
possible, called the 24-hour telephone computer rand-
omization system (toll free number) at the methods cen-
tre. The research coordinator or resident/fellow entered
their unique hospital site code, patient hospital identifica-
tion number, and the type of fracture (open, closed, or
both). Following this procedure, the computer then pro-
vided the caller with a treatment allocation (reamed or
non-reamed intramedullary nail). This procedure guaran-
teed concealed randomization. Also, the system does not
allow patients to be randomized more than once.
Each randomization package contained the following case
report forms: eligible included patient form, baseline
characteristics form, medications form (which will collect
information on NSAIDS, anti-inflammatory drugs, anti-
convulsants, oral steroids, and statins), fracture character-
istics form, surgical report form, peri-operative data form,
follow up report form (for each visit), Short Musculoskel-
etal Function Assessment questionnaire, Health Utilities
Index questionnaire, Short Form-36 questionnaire, Tibia
Knee Pain questionnaire, protocol deviation form, missed
follow up form, early withdrawal form, and excluded
patient form. Randomization packages containing all the
relevant forms were mailed to each center prior to the
study start. The research coordinator confirmed receipt
and completeness of randomization packages prior to
study start. The research coordinator at each participating
centre also ensured that all relevant case report forms were
complete and faxed to the Methods Centre as soon as
completed. Figure 1 summarizes key stages in this process.
Early after we initiated screening and recruitment across
participating sites, we identified a higher than expected
crossover rate from the non-reamed to the reamed nails.
One explanation for crossovers was the apparent enrol-
ment of patients with tibial intramedullary canals that
were too narrow to allow the passage of a smaller diame-
ter non-reamed nail. To address this issue, we revised our
randomization system to ensure that investigators con-
firmed at least a 9.5 mm diameter of the tibial intramed-
ullary canal at the isthmus (i.e. the narrowest point) prior
to randomizing the patient. This modification assured
that patients were eligible for either surgical approach.
Protecting against sources of bias
Adjudication of events
A blinded Central Adjudication Committee (CAC)
reviewed reports of all re-operations as soon as possible
after each event was reported to the methods center,
decided if a re-operation meeting study criteria had
occurred, and if so, categorized the nature of the re-oper-
ation.
All centres emailed digital photographs of the required x-
rays to the S.P.R.I.N.T. methods centre. In addition, site
coordinators mailed all relevant hospital records. All rele-
vant blinded patient records (DataFax Case Report Forms,
chart notes, and x-rays) were posted on a specially
designed, and password protected, internet website for
adjudication. We were concerned that the size of the nailBMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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would be sufficient to unmask the allocation of treatment
as non-reamed nails are smaller in diameter. To mask the
allocation of treatment, we photo-edited to crop the dig-
ital radiograph to include only the fracture site.
For those fractures that surgeons reported to have less
than 50% cortical contact between fracture ends, all adju-
dicators determined the fracture gap. For all suspected
study events, adjudicators judged the following: size of
fracture gap, re-operation planned or unplanned, appro-
priateness of re-operation, and whether it was a study
event. Any disagreements were resolved by conference
call. If adjudicators could not reach consensus, additional
information was requested from the participating site to
clarify areas of uncertainty. All decisions made by the
committee were final.
Contamination and co-intervention
Crossovers were likely to occur only when, in the operat-
ing room, the surgeon found an extremely narrow
intramedullary canal in a patient allocated to non-reamed
nailing and undertook limited reaming to allow insertion
of a nail. Any patients who did cross were analyzed in the
group to which they were allocated, maintaining the
intention to treat approach we planned for the analysis.
Surgical co-intervention, such as a general, neurosurgical
or orthopaedic procedure, were likely to confound out-
comes. Our standardization of management protocols
limited co-intervention, and we documented the use of
drugs that affected the bone, and major additional proce-
dures that patients underwent (Table 2).
Recruitment and Follow-Up Schedule Figure 1
Recruitment and Follow-Up Schedule.
Data Collected     
Identification of Patients                  Direct referral-within centre,  
                                                             or between centres 
 
 
Assessment of Patient Eligibility       Study explanation 
             History-review eligibility criteria,    Eligibility Form   
             and other relevant medical conditions   
             Physical Examination               Baseline Characteristics Form  
              R a d i o g r a p h s         
             Informed Consent, if eligible      Informed Consent   
 
                                              All eligible patients who consent to the trial 
 
 
Randomization           24 HOUR TOLL FREE NUMBER 
                         Eligibility criteria reviewed again 
               Key information recorded       Randomization Form at 
     a t   M e t h o d s   C e n t r e       M e t h o d s   C e n t r e    
             Randomization issued to patient                                          
 
 
 
Surgery             Either reamed or non-reamed         Surgical Report Form 
                            surgical protocols will be followed 
 
 
 
Follow-Up Schedule 
 
Hospital Discharge    Assessment of outcome events      Follow-Up Form, SF-36,  
HUI, SMFA, Tibia Knee Pain Questionnaire 
 
2 Week Post-Discharge    Assessment of outcome events      SF-36, HUI 
 
6 Week Post-Surgery    Assessment of outcome events      Follow-Up Form 
 
3   Month      Assessment of outcome events       Follow-Up Form, SF-36,  
HUI, SMFA  
     
6   Month      Assessment of outcome events         Follow-Up Form, SF-36,  
HUI, SMFA 
     
9   Month      Assessment of outcome events       Follow-Up Form 
         
12 Month      Assessment of outcome events      Follow-Up Form, SF-36,  
HUI, SMFA, Tibia Knee Pain
Questionnaire,  
12 month Follow-Up Form BMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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Study eligibility criteria
Inclusion criteria.1. Men or women who were skeletally
mature (age 18 years or older) 2. Fracture of the tibia that
had complete anterioposterior and lateral radiographs 3.
Closed or open fractures (Tscherne Grade 0–3, Gustillo
Grade I-IIIB) [57-59]4. Fracture that required operative
treatment (failure to maintain alignment with conserva-
tive treatment). 5. Provision of informed consent.
Individuals were excluded from the study if they had the
following characteristics:
1. Fractures were not amenable to intramedullary nailing
(<5 cm distal to the tibial tubercle, or < 5 cm proximal to
the tibiotalar joint). 2. Inability to pass an unreamed nail.
3. Fractures that had associated neurovascular deficits
(Gustillo Grade IIIC injuries) [58,59]. 4. Pathologic frac-
tures. 5. Surgical delay of > 12 hours from time of injury
(open fractures) [60]. 6. Surgical delay of > 3 weeks from
time of injury (closed fractures). 7. Retained hardware in
the affected limb that interfered with intramedullary nail-
ing. 8. Associated fractures of the foot, ankle, or knee. 9.
Likely problems, in the judgment of the investigators,
with maintaining follow-up. We excluded, for example,
patients with no fixed address, those who reported a plan
to move out of town in the next year, or intellectually
challenged patients without adequate family support.
Participating centers identified patients through direct
referral. Each surgeon or designated fellow or resident
conducted a history and physical examination and com-
pleted a check list based upon study eligibility. The resi-
dent/fellow or research coordinator obtained informed
consent. Figure 1 outlines the key aspects of the recruit-
ment.
We registered all patients who met the inclusion criteria
and documented reasons for failure to randomize. The
CAC adjudicated all situations where eligibility was in
doubt. The CAC included the Study Biostatistician (SW),
the Principal Investigator (MB, orthopaedic surgeon), the
co-principal investigator (GHG, internist/methodologist),
and four orthopaedic surgeons (PT, MFS, DS, EHS).
After the first interim analysis (N = 332 patients), we
expanded the eligibility criteria to allow surgeons to use
their own best judgment to determine if the fracture was
amenable to intramedullary nailing. Specifically, sur-
geons did not exclude patients whose fractures were <5 cm
distal to the tibial tubercle, or <5 cm proximal to the tibi-
otalar joint if they judged it as amenable to intramedul-
lary nailing. We also revised our exclusion criteria #8
above to the following: Surgeons could randomize a
patient if the fractures did not interfere with the intramed-
ullary nailing. We also allowed fractures that could be sep-
arately fixed without compromising placement of an
intramedullary nail.
Frequency and duration of follow-up
Follow up continued for a period of one year. At the one-
year follow up visit, the surgeon also documented any re-
operations that were planned for the patient after one-
year. Clinical and radiographic assessments occurred at
the time of admission to hospital (baseline), hospital dis-
charge, 2 weeks post discharge, 6 weeks, 3, 6, 9, and 12
months post-intramedullary nailing (Figure 1). Follow up
Table 2: Major additional procedures in S.P.R.I.N.T patients
Total (%) Reamed (%) Non-Reamed(%)
Additional Procedures (n,%)†
Yes 310 (25.3) 166 (26.7) 144 (23.8)
Fixation of other LE fracture 132 (42.6) 74 (44.6) 58 (40.3)
Fixation of UE fracture 65 (21.0) 30 (18.1) 35 (24.3)
Fixation of pelvic/acetabular 17 (5.5) 11 (6.6) 6 (4.2)
Upper extremity amputation 0 (0.0) 0 (0.0) 0 (0.0)
Fixation of non-eligible tibial f 27 (8.7) 12 (7.2) 15 (10.4)
Laparotomy 8 (2.6) 3 (1.8) 5 (3.5)
Lower extremity amputation 2 (0.6) 1 (0.6) 1 (0.7)
Craniotomy 4 (1.3) 4 (2.4) 0 (0.0)
Spine fracture 4 (1.3) 3 (1.8) 1 (0.7)
Removal hardware 7 (2.3) 3 (1.8) 4 (2.8)
Other wound closure 91 (29.4) 53 (31.9) 38 (26.4)
Fasciotomy 8 (2.6) 5 (3.0) 3 (2.1)
Fixation of facial fracture 2 (0.6) 1 (0.6) 1 (0.7)
Drain insertion 1 (0.3) 0 (0.0) 1 (0.7)
Knee dislocation repair 2 (0.6) 0 (0.0) 2 (1.4)
(given as % of those with additional fractures)
No 916 (74.7) 456 (73.3) 460 (76.2)BMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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assessment included subsequent operative procedures,
the reason for the procedure, and functional status.
Two factors dictated the choice of 1 year follow up period:
1) All participating surgeons agreed that the decision to re-
operate on a tibial fracture would occur within the first
year following surgery in all, or virtually all, patients. 2)
Previous randomized trials had reported closed tibial frac-
tures to heal at a mean 3.9 months [48] and open tibial
fractures to heal at a mean 7 months [44]. Thus, all of the
closed fracture re-operations, and over 95% of the open
fracture re-operations, occur within one year. Since
increasing follow up beyond one year would yield very lit-
tle additional information on re-operation rates, efficient
use of resources dictated a one-year follow up.
Outcome measures
Primary outcome
We originally described our primary outcome as re-opera-
tion within 1 year of the initial surgery. Surgical proce-
dures considered as primary events included: 1) bone
grafts, 2) implant exchange or removal (broken nail or
deep infection), and 3) debridement of bone and soft tis-
sue from deep infection. We assessed re-operation at fol-
low up visits of hospital discharge, 6 weeks, 3 months, 6
months, 9 months, and 1 year. The attending physicians
documented any subsequent operative procedure directed
specifically towards improving fracture healing at each
follow up visit.
After the first interim analysis in January 2003, when 332
patients had been enrolled, the event rate was substan-
tially lower than anticipated from our review of previous
studies. In response, we proposed, and both the Data
Safety and Monitoring Committee (DSMB) (National
Institutes of Arthritis, Musculoskeletal and Skin diseases,
NIAMS) and the primary funding agency (CIHR)
accepted, the adoption of an expanded primary compos-
ite outcome. The new primary outcome included re-oper-
ation within 1 year of initial surgery in patients with
cortical continuity, or less than 1 cm gap between the frac-
ture ends post intramedullary nailing (Table 3). Specific
eligible procedures in the composite endpoint included
the following: 1) nail replacement, 2) operation for infec-
tion, 3) dynamization, 4) removal of locking screw(s) due
to hardware breakage (autodynamization) or loosening
of screws, 5) drainage of hematomas, and 6) fasciotomy
for intra-operative or post-operative compartment syn-
drome.
Eligible events: To limit a potential bias against the non-
reamed nail group among participating surgeons, we pro-
scribed re-operation within the first 6 months following
surgery. This allowed sufficient time for most fractures to
heal. The only exceptions were subsequent soft tissue cov-
erage procedures, debridement if infection occurred, and
nail replacement if nail breakage occurred. Dynamization
was allowed prior to 6 months only if a fracture gap
remained following insertion of the intramedullary nail.
To identify any deviations in protocol, re-operations were
noted at the earlier follow up periods (hospital discharge,
6 weeks, and 3 months).
We did not consider the following procedures as study
events: 1) re-operations planned at the time of initial sur-
gery; 2) re-operations or dynamizations in patients with a
fracture gap of greater than or equal to 1 cm; 3) removal
of proximal or distal locking screws after six months that
did not dynamize the fracture; 4) soft tissue coverage in
the absence of infection; 5) in open fractures, copious irri-
gation and debridement of soft tissues and contaminated
bone repeated as necessary following the initial nailing; 6)
amputations; 7) treatment of wound or tissue necrosis in
the absence of infection; and 8) re-operations to correct
an unacceptable degree of mal-alignment following the
initial nailing.
Criteria for undertaking a bone graft included: 1) a frac-
ture with a ≥ 1 cm fracture gap and at least 50% circumfer-
ential bone loss at the fracture site and 2) failure of
progression of fracture healing for at least 2 months
accompanied by clinical symptoms of delayed/nonunion
(pain, difficulty weight bearing). Criteria to permit
exchange intramedullary nailing included: 1) a <1 cm
fracture gap and at least 50% circumferential bone loss
[61] and 2) failure of progression of the fracture to heal
for at least 2 months accompanied by clinical symptoms
of delayed/nonunion (pain, difficulty weight bearing).
Table 3: Fracture gaps, protocol deviation status, and study event status
Size of Fracture Gap at the Time of the Initial Surgery* Protocol Deviation if Re-Operation before 6 Months** Study Event
0 (no fracture gap) Yes Yes – Primary Event
Fracture gap less than 1 cm Yes Yes – Primary Event
Fracture gap greater than or equal to 1 cm No No
* This refers to the magnitude of circumferential bone loss as judged by the adjudicator on review of the post-operative radiograph, or non-
circumferential bone loss as judged by the adjudicator in the presence of cortical continuity of 0 or 25% as judged by the surgeon at the time of 
operation and recorded on our study forms.
** For nonunion, malunion, dynamization, not infectionBMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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We classified the reasons for re-operation as follows: non-
union, malunion (>5 degrees varus/valgus, >10 malrota-
tion degrees, and >1 cm shortening) [62], compartment
syndrome, and infection. Criteria for the diagnosis of
nonunion included a failure of the fracture to progress
towards healing for at least 2 months (although no sec-
ondary procedures were allowed for 6 months following
the initial intramedullary nailing). This was evident as a
persistent fracture line on radiograph and pain on palpa-
tion at the fracture site, or the inability to weight bear
without pain. We have previously characterized the relia-
bility of utilizing cortical continuity and fracture lines in
the assessment of fracture healing [72].
Secondary outcome
We measured functional status as a secondary outcome.
Patients completed self-administered functional outcome
questionnaires under research coordinator supervision at
hospital discharge, 2 weeks post discharge, 6 weeks, and
3, 6, 9, and 12 months post-surgery. Questionnaires
included a generic health status measurement instrument,
the SF-36 [63-65], a generic utility measure (the Health
Utilities Index Mark II/III) [66-68], a disease-specific func-
tional measure targeted to patients with lower extremity
fractures (Short Musculoskeletal Function Assessment
measure, SMFA) [69,70] and a tibial knee pain question-
naire.
The SF-36 questionnaire was developed from the Medical
Outcomes Study [63,64]. It is a self-administered, 36 item
questionnaire that measures health-related quality of life
in eight domains:1) physical functioning, by measuring
the ability to perform a variety of daily activities and tasks
that require physical effort (10 items); 2) role limitations
due to physical problems(4 items); 3) role limitations due
to emotional problems (3 items); 4) vitality, measuring
perceived level of energy and fatigue (4 items); 5) freedom
from bodily pain (2 items); 6) social functioning (2
items); 7) mental health, by measuring both negative and
positive emotional states (5 items); and 8) general health
perceptions (6 items). The instrument has been exten-
sively validated and has demonstrated good construct
validity, high internal consistency, and high test- retest
reliability [63,64]. We considered an important difference
to correspond to a moderate effect as defined by Cohen
[73] as well as a minimally important difference in the SF-
36 as reported by Ware [63]. In both cases, the value is 1/
2 the standard deviation, equivalent to a 7 point differ-
ence in score. Specifying an alpha (α) level = 0.05, a
beta(β) = 0.20 (study power = 80), we required a sample
of at least 30 patients to ensure detection of a 1/2 standard
deviation improvement.
The Short Musculoskeletal Function Assessment (SMFA)
is a 46 item questionnaire that has 6 domains: 1) daily
activities, 2) emotional status, 3) arm and hand function,
4) mobility, 5) function index and 6) bothersome index.
It has been validated as a measure of patient function
[69,70].
As part of a subsequent research protocol for an economic
analysis we collected patient utilities utilizing the HUI
MarkII/III [66-68].
Additional secondary outcomes included dynamization
rates, deep infection rates (bone implant interface), com-
partment syndrome rates and malunion rates (>5 degrees
varus/valgus, >10 malrotation degrees, and >1 cm short-
ening) [62]. Each of these outcomes will be assessed at fol-
low up visits.
Statistical issues
Sample size
Our choice of sample size was based on the anticipated
rate of the primary outcome (re-operation). All statistical
hypotheses were two-sided. We chose alpha levels of 0.05
for the primary and 0.01 for the secondary outcomes. We
evaluated 7 secondary outcomes, but because they were
likely to be correlated the Bonferroni correction would
have been excessively conservative we chose not to use
this approach. The trial was designed to have a statistical
power of 80% for the primary comparison.
Previous studies have reported annual re-operation rates
in tibial fracture patients which have ranged from
12–44%, with a weighted pooled risk of 31.6 % (95%
confidence intervals: 24.9–39.1%) [43]. After conducting
our first blinded interim analysis (N = 332 patients) of
patients followed for 1 year, our primary event rate (13%)
proved lower than projected from previous RCTs. A
number of factors account for our lower rate of re-opera-
tion. First, our strict protocol for optimal peri-operative
management improved patient care. This improvement in
care has, we believe, decreased the frequency of re-opera-
tions. Second, our proscription of re-operations for
delayed healing prior to six months was a feature not reg-
ulated in previous studies [43-54]. Third, we excluded re-
operations in patients with fracture gaps ≥ 1 cm because it
is extremely implausible that the type of nail affects the
success in achieving union in such patients. The interven-
tion may still affect infection rates because of the compro-
mise of blood supply associated with reaming. Thus,
including re-operations for failure to heal (but not for
infection) in such patients would increase the random
error in the comparison of the two types of nailing with
respect to our primary outcomes. Prior studies included
re-operations for failure to heal in patients with fracture
gaps greater than 1 cm. Of our first 74 patients with re-
operations, 10 had fracture gaps greater than 1 cm and of
these, all had re-operations because of failure of union.BMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
Page 10 of 15
(page number not for citation purposes)
With our event rate of 13%, an additional 300 patients
(total sample size = 1200 patients) provided adequate
study power (87%) for a treatment effect of at least 37%.
We planned a priori to separately compare the effects of
reamed versus nonreamed intramedullary nailing in
patients with closed and with open tibial shaft fractures.
We adjusted all analyses for important prognostic factors.
Our interim analysis suggested about 30% of our patients
had open fractures (101/332). Thus, we anticipated 360
patients (180 per treatment arm) with open fractures at
the conclusion of our trial. With an event rate of 20%
from the interim analysis of open fractures (N = 332
patients), our study would have 81% power to detect a
55% relative risk reduction (RRR), 72% power for a 50%
RRR, 49% power for a 40% RRR and 38% power for a
35% RRR in re-operation risk with reamed nails. If our
point estimate from our previous meta-analysis was cor-
rect (RRR = 56%) [43], we would have adequate study
power for our analysis.
Analysis
Our primary analysis followed the intention-to-treat prin-
ciple and compared the proportion of patients with a re-
operation in the reamed group to the proportion of
patients with a re-operation in the non-reamed group at 1
year follow up using a Mantel-Haenszel stratified analysis.
We stratified by center and whether the fracture was open
or closed. The results of the primary analysis were pre-
sented as a relative risk. In addition to the analysis of our
primary composite outcome, we also compared the occur-
rence of each component of the composite in the two
groups.
Additional analyses, employing log binomial regression,
examined and controlled for the influence of patient and
surgical factors that were hypothesized a priori to be asso-
ciated with the risk of re-operation, including age, smok-
ing history, diabetes, fracture location (Proximal, Middle,
Distal), fracture comminution (Orthopaedic Trauma
Association fracture type), fracture grade (Gustilo or
Tscherne grading) and unilateral versus bilateral fractures.
Subgroup analyses were conducted using tests for interac-
tions; all were specified a priori. Our subgroup analysis of
primary interest was open versus closed fractures. Addi-
tional subgroup hypotheses included impact of treatment
in multi-trauma versus isolated fractures; unilateral versus
bilateral tibial fractures; OTA classification C types vs. B
and A; surgeries performed by surgeons versus fellows and
residents; and fracture gaps greater than versus less than,
or equal to, 1 cm. Within open fractures, we considered
subgroups of Types IIIA and IIIB vs. Types I-II. Within
closed fractures, we considered subgroups of Tscherne
Types 2–3 vs. 0–1 fractures.
Blinded results were initially presented to the Steering
Committee members as treatment A and treatment B.
Prior to unblinding themselves, Steering Committee
members developed two alternative interpretations of the
results if A were the 'reamed group' or if A were the
'unreamed' group.
Frequency of analyses
We conducted one interim analysis after 322 patients had
completed the trial. The data analyst presented the results
of these analyses, including confidence intervals, to an
independent Data Safety and Monitoring Committee
(DSMB). DSMB members were guided by the O'Brien-
Fleming stopping rule. In choosing the significance level
for the interim analysis to maintain the overall specified
type I error rate of 0.05. In the interim analysis, we set the
significance level at 0.0006 thus maintaining a signifi-
cance level of 0.05 for the final analysis. This method was
conservative, making it difficult to stop the trial early
unless a large difference between treatments was
observed. No one other than committee members were
aware of the interim results, and only the DSMB commit-
tee members were aware of the content of their delibera-
tions.
Compliance
We instituted several strategies to ensure adherence to the
protocol which including: 1) weekly quality report forms
to flag protocol violations, 2) monthly newsletters re-
emphasizing important aspects of the protocol, 3) imme-
diate personal telephone calls from the Principal Investi-
gator, or Project Manager to site investigators when
protocol violations occurred, 4) 24 hour pager for any
queries regarding the study protocol, and 5) annual inves-
tigator meetings to discuss protocol violations and strate-
gies to improve adherence. These strategies led to
adherence rates of over 90% in important aspects of the
study protocol among the first 332 patients included.
Given the inherent variability in practice patterns among
orthopaedic surgeons, it was important to ensure that sur-
geons adhered as closely as possible to the surgical man-
agement protocol. In general, large studies involving
multiple centres are more feasible if they require minimal
changes from current practice. To limit bias that could
occur if participating surgeons have different re-operation
criteria for reamed and non-reamed nail groups, we pro-
scribed re-operation within the first 6 months following
surgery.
Crossovers that occur at the time of surgery are another
important protocol violation. In our first 620 patients
enrolled, we identified a total of 33 (5.3%) crossovers
across both surgical interventions. In response to the
higher than expected crossover rate, the Steering Commit-BMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
Page 11 of 15
(page number not for citation purposes)
tee reinforced the importance of adherence to protocol
via: 1) direct telephone calls from the Principal Investiga-
tor to each site at which a crossover had occurred, 2) a
conference call of all site investigators to highlight this
finding, and 3) a focused discussion of protocol violation
at our annual investigators' meeting.
Loss to follow-up
Previous randomized trials in orthopaedic surgery have
typically reported 10% but up to 30% loss to follow up of
included patients [43-52]. To avoid this problem and
achieve high follow-up rate we successfully implemented
the following procedures: 1) We excluded individuals
who were likely to be difficult with follow-up (see exclu-
sion criteria). 2) At the time of randomization, each
patient provided their own address and phone number,
the name and address of their primary care physician, and
the name, address and phone number of three people at
different addresses with whom the patient did not live
who were likely to be aware of the patient's whereabouts.
The research coordinator confirmed that these numbers
were accurate prior to the patient's discharge from hospi-
tal. 3) Participants received information on tibial frac-
tures, their complications and the potential treatment
effects, expectations for personal benefit from study par-
ticipation, and motivation for adherence with follow up
visits and research protocols. Aids used for education and
support included a patient information booklet, a tele-
phone number for advice in case of complications or
questions regarding follow up visits. 4) Patients received
reminders for upcoming clinic visits from local study per-
sonnel. 5) Follow up schedules coincided with normal
surgical fracture clinic visits. 6) Study personnel contacted
patients at least once every three months to obtain infor-
mation about any planned change in residence. 7) If a
patient refused to return for a follow up assessment, his/
her status with regard to re-operation or any secondary
outcome was determined by telephone contact with the
patient, alternate contact, or the family physician.
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Mitchel Brion Harris; Ethan Ron Wiesler; William G.
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versity School of Medicine, Boston, Massachusetts: Paul
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pher T. Bono; Thomas A. Einhorn; T. Desmond Brown;
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Cole; Joel J. Smith; Gregory A. Brown; Thomas A. Lange;
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Schutte; Linda (Toddie) Tastad; Sandy Vang; University of
Louisville School of Medicine, Louisville, Kentucky:
David Seligson; Craig S. Roberts; Arthur L. Malkani; Laura
Sanders; Sharon Allen Gregory; Carmen Dyer; Jessica
Heinsen; Langan Smith; Sudhakar Madanagopal; Memo-
rial Hermann Hospital, Houston, Texas: Kevin J. Coupe;
Jeffrey J. Tucker; Allen R. Criswell; Rosemary Buckle; Alan
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Thea Trotscher; Erie County Medical Center/University
of Buffalo, Buffalo, New York: Mark J. Anders; Joseph M.
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M. Mihalko; Cathy Buyea; University of Florida – Jack-
sonville, Jacksonville, Florida: Stephen J. Augustine; Wil-
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June McAdams; Academic Medical Center, Amsterdam,
The Netherlands: J. Carel Goslings; Kees Jan Ponsen; Jan
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Raphaël Duivenvoorden; University of Oklahoma
Health Science Center, Oklahoma City, Oklahoma:
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J. J. Ertl; Timothy A. Puckett; Charles B. Pasque; John F.
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System, Greenville, South Carolina: Kyle J. Jeray; David
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Calgary, Alberta: James N. Powell; Richard E. Buckley;
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Discussion
Trials in orthopaedic surgery have typically been single
center initiatives that often lack sufficient power to make
recommendations regarding surgical practice, and suffer
from methodological limitations. This is the first large
scale co-operative trial among orthopaedic traumatolo-
gists in North America and Europe to assess an orthopae-
dic surgical treatment. Our team of investigators will be
able to work towards answering many other important
questions in orthopaedic surgery. This trial will also estab-
lish a model for multi-center co-operative trials in ortho-
paedic trauma, which, over the long term, will have the
same sort of impact as large trials in cardiovascular medi-
cine and cerebrovascular surgery.
S.P.R.I.N.T has important strengths including a large sam-
ple of enrolled patients, multiple participating surgeons
and centers, a patient-important outcome with independ-
ent adjudication and improved methodological rigor in
the conduct of the trial (including a proscription to re-
operation before 6 months).
A major strength of our study was the assurance of alloca-
tion concealment with remote 24 hour randomization.
The extent to which previous smaller randomized trials
maintained concealment remains questionable. Lack of
allocation concealment in trials has been shown to over-
estimate treatment effects. S.P.R.I.N.T's sample size is ten-
fold greater than the largest previous randomized trial
evaluating reamed and non-reamed tibial nails. Based on
previous trials and our beliefs that treatment effects would
be conserved across open and closed fractures, S.P.R.I.N.T
is powered to detect patient-important differences in re-
operation risk.
One major methodological safeguard employed in
S.P.R.I.N.T but not in previous studies was the 6 month
proscription of re-operation. Previous trials with large
reported benefits to reamed nails and S.P.R.I.N.T sur-
geons' increased experiences with reamed nails risked aBMC Musculoskeletal Disorders 2008, 9:91 http://www.biomedcentral.com/1471-2474/9/91
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differential threshold towards early re-operation in
patients randomized to non-reamed nail insertion. Our
choice of 6 months was based on a consensus of partici-
pating surgeons that, if left alone, 6 months was adequate
to allow most treated fractures to heal in either group.
One major limitation of S.P.R.I.N.T was the fact that sur-
geons could not be blinded to treatment allocation leav-
ing the assessment of outcomes and decisions to re-
operate vulnerable to bias. To limit such bias, we used an
objective primary outcome and independently adjudi-
cated all primary outcome events by a committee of 7
members, of whom 5 were orthopaedic trauma surgeons.
The primary composite outcome of re-operation provides
a patient-important estimate of effect superior to previ-
ously described measures such as radiographic fracture
healing, delayed unions, and nonunions.
S.P.R.I.N.T, as any trial evaluating two procedures requir-
ing technical experience, risked differential expertise bias
[72]. In a survey of 139 S.P.R.I.N.T surgeons (response
rate: 74, 52%), 55% had used the reamed nailing tech-
nique in at least 20 patients in the year preceding the trial
whereas only 19% used non-reamed nail insertion. The
median number of cases surgeons had performed in the
year before participation in S.P.R.I.N.T. was 12 reamed
procedures and 2 non-reamed procedures (median differ-
ence 7 procedures, 95% confidence interval 5 to 11). The
extent to which a differential expertise bias was operating
in S.P.R.I.N.T remains unknown.
The treatment of tibial fractures remains controversial.
Identifying treatment alternatives that reduce the risk of a
subsequent operation as well as costs to the health care
system will be a significant contribution to the practice of
orthopaedics. This trial will not only change current
orthopaedic practice, but will set a benchmark for the con-
duct of future orthopaedic trials.
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